Logo do repositório
 
Publicação

Nirsevimab effectiveness against hospitalised Respiratory Syncytial Virus infection in Portugal, 2024/25 season

2025-11Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorGaio, Vânia
dc.contributor.authorValadas Henriques, Camila
dc.contributor.authorLança, Miguel
dc.contributor.authorMachado, Ausenda
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorRodrigues, Ana Paula
dc.date.accessioned2026-03-03T16:56:11Z
dc.date.available2026-03-03T16:56:11Z
dc.date.issued2025-11
dc.description((MAPEAR COM DDI))
dc.description.abstractBackground: Respiratory Syncytial Virus (RSV) is one of the leading causes of lower respiratory tract infections in younger children. In mainland Portugal, in order to reduce the risk of severe RSV post-infection complications, an immunisation strategy using Nirsevimab was implemented starting in October 2024, targeting all children aged less than 3 months, and those with high-risk conditions less than 24 months. We conducted a test-negative case-control study using the national hospital-based RSV surveillance network to estimate Nirsevimab effectiveness (NE). Methods: This multicentre study included children aged under 24 months hospitalised with severe acute respiratory infection in 14 hospitals. Cases were defined as children testing positive for RSV by RT-PCR or rapid antigen test (RAT), while controls tested negative. Immunisation status was obtained from electronic medical records. NE was estimated using logistic regression and estimated as (1 – adjusted odds ratio of immunisation) × 100, adjusting for age group, sex, month of symptom onset date, low birth weight, prematurity, and chronic conditions. Results: Between weeks 40/2024 and 12/2025, we included 111 cases and 110 controls. The median age for both groups was 2 months (IQR: 1–4). 44 (39.6%) RSV-positive and 80 (72.7%) RSV-negative infants received Nirsevimab at least 2 days before symptom onset. No significant differences were observed between cases and controls regarding sex or medical conditions. NE against RSV-associated hospitalisation was 85% (95% CI: 66–94) in the target population. Sensitivity analysis restricted to RT-PCR-confirmed cases yielded similar results. Conclusions: During the first immunisation season in mainland Portugal, Nirsevimab conferred good protection against the most severe presentation of RSV infection in young children. Our results are aligned with those reported in other countries. Given the potential for viral evolution following the introduction of universal immunisation programmes, ongoing monitoring of NE is warranted.eng
dc.identifier.urihttp://hdl.handle.net/10400.18/11057
dc.language.isoeng
dc.peerreviewedn/a
dc.rights.uriN/A
dc.subjectNirsevimab
dc.subjectVigiRSV
dc.subjectDeterminantes da Saúde e da Doença
dc.subjectObservação em Saúde e Vigilância
dc.subjectEstados de Saúde e de Doença
dc.subjectInfecções Respiratórias
dc.titleNirsevimab effectiveness against hospitalised Respiratory Syncytial Virus infection in Portugal, 2024/25 seasoneng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2025-11-19
oaire.citation.conferencePlaceWarsaw, Poland
oaire.citation.titleEuropean Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), 19-21 November 2025
oaire.versionhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43
person.familyNameGaio
person.familyNameValadas Henriques
person.familyNameMachado
person.familyNameGuiomar
person.givenNameVânia
person.givenNameCamila
person.givenNameAusenda
person.givenNameRaquel
person.identifier.ciencia-idA71A-17AF-30C7
person.identifier.ciencia-id851F-4E5E-D0AD
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.orcid0000-0001-7626-4991
person.identifier.orcid0000-0002-3654-4929
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0002-4563-6315
person.identifier.scopus-author-id56080468200
relation.isAuthorOfPublication59791814-187c-4b34-b3a2-6ad67a213814
relation.isAuthorOfPublication6fe03523-acfc-4a28-ba2d-ab0d9b911d1e
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication.latestForDiscovery59791814-187c-4b34-b3a2-6ad67a213814

Ficheiros

Coleções

DEP - Apresentações orais em encontros internacionais
DDI - Apresentações orais em encontros internacionais